Agios Pharmaceuticals, a Cambridge, Mass.-based cancer drug developer, secured $106 million from its initial public offering. The shares of common stock sold and their price exceeded the company's projections. The company specializes in therapies for cancer and inborn errors of metabolism, and two of its cellular metabolism-targeting drug candidates are in development with Celgene.

Related Summaries